Early Treatment Response
Cross-source consensus on Early Treatment Response from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- A delayed treatment response is associated with erosive disease, functional impairment, and worse long-term quality of life. — PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach
- An inadequate tsDMARD response at month 4 creates an actionable point for switching earlier to a bDMARD. — PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach
- A one-month glucocorticoid response serves as a clinical proxy for molecular predictors of conventional DMARD response. — PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach
- TNF inhibitors are often first biologic choices, but about one-third of patients respond inadequately. — PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA) trial: a multicentre, open-label, randomised controlled trial comparing routine care with a tailor-made approach